Key Highlights
- argenx's Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective.
- The combined IMNM/DM group showed a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.
- The IMNM cohort saw significant benefit, while the smaller DM subgroup showed meaningful but not statistically significant results.
- The safety profile remained in line with previous efgartigimod research.
argenx SE (NASDAQ: ARGX) announced that its Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective, with the combined IMNM/DM group demonstrating a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.
What Happened
The smaller DM subgroup showed clinically meaningful results that lacked statistical significance, while the IMNM cohort saw significant benefit, all while maintaining a safety profile in line with previous efgartigimod research.
Market Reaction
The disclosed information does not include stock price or trading data for argenx following the Phase 3 ALKIVIA results.
Outlook
The split results between the IMNM and DM subgroups are likely to be a key focus for regulators and investors as argenx determines its regulatory strategy for Vyvgart Hytrulo in autoimmune myositis.
FAQs
Q: Did argenx's Phase 3 ALKIVIA trial meet its primary endpoint?
A: Yes, the combined IMNM/DM group showed a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.
Q: Did both patient subgroups show statistically significant results?
A: The IMNM cohort saw significant benefit, while the smaller DM subgroup showed clinically meaningful but not statistically significant results.
Q: How did the trial's safety profile compare to prior data?
A: The safety profile remained in line with previous efgartigimod research.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.